معرفی
Paul A. Wender is the Francis W. Bergstrom Professor of Chemistry at Stanford University, with a courtesy appointment in the Department of Chemical and Systems Biology. His research spans chemistry, biology, and medicine, with a focus on synthesis and design to address significant problems including HIV/AIDS eradication, overcoming resistant cancer, and treating cognitive disorders like Alzheimer's disease.
Education:
- B.S. in Chemistry, Wilkes University (1969)
- Ph.D. in Chemistry, Yale University (1973)
- NIH Postdoctoral Fellow, Columbia University (1974)
Professor Wender's research emphasizes step economy and function-oriented synthesis, developing new reactions and strategies for efficient molecule construction. His work spans organic synthesis, chemical biology, and drug discovery, with special focus on molecular transporters for drug delivery, new therapeutic strategies for challenging diseases, and computational tools for molecular design. His group leverages affiliations with Stanford's Medical School, Imaging Center, Chemical Biology Program, and Molecular Therapeutics Program.
Recent publications reveal a strong focus on mRNA delivery systems, particularly using charge-altering releasable transporters (CARTs) for targeted therapy. His work spans HIV latency reversal, cancer immunotherapy, antibiotic development, and treatment of neurological disorders, demonstrating interdisciplinary collaboration across chemistry, biology, and medicine.
Scientific Awards:
- Tetrahedron Prize for Creativity in Organic Chemistry (2012)
- Prelog Medal from ETH Zurich (2013)
- Arthur C. Cope Award from American Chemical Society (2015)
- Cohen Award for Excellence in Medicinal Chemistry (2015)
- Sir Derek Barton Gold Medal Award (2024)
- Elected member of the US National Academy of Sciences (2003)
- Foreign member of the Royal Spanish Academy of Sciences (2013)
Professor Wender mentors a diverse research group including PhD students, postdoctoral scholars, and undergraduate researchers. His lab has received substantial funding from NIH, including multiple MERIT Awards, supporting research on HIV eradication, cancer therapy, and drug delivery systems. The Wender Group collaborates extensively with biotech and pharmaceutical industries, translating basic research into potential therapeutics.
The Wender Group is affiliated with numerous Stanford programs including Bio-X, the Center for Molecular Analysis and Design, the Institute of Chemical Biology, the Molecular Imaging Program, the Cancer Center, and the Cancer Nanotechnology Program. Their research integrates synthetic chemistry, mechanistic studies, and biological evaluation to develop transformative approaches in medicine.
